Results 61 to 70 of about 176 (130)

Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

open access: yesMedComm, Volume 7, Issue 3, March 2026.
Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu   +9 more
wiley   +1 more source

Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2011
BACKGROUND: Real time PCR has become the most common technique to monitor BCR-ABL transcript levels of patients treated with kinase inhibitors. The aim of this study was to evaluate BCR-ABL levels of chronic myeloid leukemia patients treated with ...
Melissa Pereira Machado   +8 more
doaj   +1 more source

Dual Proteasome and Histone Deacetylase Inhibition Overcomes Tyrosine Kinase Inhibitor Resistance in Breakpoint Cluster Region: Abelson 1‐Driven Leukaemia Cell Lines

open access: yesJournal of Cellular and Molecular Medicine, Volume 30, Issue 4, February 2026.
ABSTRACT Resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in breakpoint cluster region (BCR)::Abelson 1 (ABL1)‐driven leukaemias. Asciminib offers a novel therapeutic option; however, resistance continues to emerge. We hypothesised that targeting proteostasis and epigenetic regulation with bortezomib and panobinostat could ...
Seiichi Okabe   +4 more
wiley   +1 more source

Interferon-alpha-Treated Patients with Chronic Myelogenous Leukemia Show BCR/ABL-Positive Peripheral Blood Progenitor Cells Surviving Long-Term Culture

open access: yesFolia Biologica, 2000
Several groups have shown that Ph-progenitors reappear in LTC of CML bone marrow or PBMNC when the cell preparations were derived from newly diagnosed Ph-positive patients or after induction chemotherapy. We have tested the hypothesis whether LTC may further decrease CML progenitors if the cells to be cultured were from IFN-treated
B, Schultheis   +4 more
openaire   +2 more sources

Recommendations from a Portuguese Expert Group for Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients in Clinical Practice

open access: yesActa Médica Portuguesa, 2019
Until recently, the main goal of chronic myeloid leukemia therapy was disease control with the best overall survival, which required lifelong treatment.
Antonio Almeida   +10 more
doaj   +1 more source

Excellent Survival Following Low‐Intensity Approaches Prior to Allo‐HSCT in Ph+ ALL: A Comprehensive Meta‐Analysis

open access: yesAdvances in Hematology, Volume 2026, Issue 1, 2026.
Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL) is a therapeutic challenge, particularly for elderly patients and those with comorbidities. While traditional intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is highly effective, therapy‐related toxicity and mortality is a ...
Lacey S. Williams   +9 more
wiley   +1 more source

Multifaceted Small Molecules as Enzyme Modulators: Cases of Drug Discovery/Repurposing Illustrating Nature′s Pragmatism

open access: yesBioMed Research International, Volume 2026, Issue 1, 2026.
The cross‐reactivity of substrates, modulators with other enzymes significantly reduces/prevents our ability to design such highly specific, that is, “one warhead–one target”, modulators. On the other hand, the potential “impasse” fuels repurposing of already developed drugs.
Monika I. Konaklieva   +2 more
wiley   +1 more source

TREATMENT WITH IMATINIB MESILAT IN CHRONIC MYELOGENOUS LEUKEMIA – OUR EXPERIENCE

open access: yesZdravniški Vestnik, 2004
Background. Chronic myelogenous leukemia (CML) is a malignant clonal disorder of hematopoietic stem cell. In majority of patients we find reciprocal chromosomal translocation t (9.22) which result in fusion oncoprotein with tyrosine kinase activity.
Mateja Grat, Joško Vučkovič
doaj  

MXene‐Based Electrochemiluminescence (ECL) Biosensors: A Review on Analyte Detection and Diagnostic Applications

open access: yesMedComm – Biomaterials and Applications, Volume 4, Issue 4, December 2025.
This review highlights recent advances in MXene‐based electrochemiluminescence (ECL) biosensors, showcasing their exceptional sensitivity and versatility in detecting biomolecules, pathogens, and environmental pollutants. The integration of MXenes significantly enhances ECL signal amplification, paving the way for next‐generation diagnostic and ...
Kai Zhang
wiley   +1 more source

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes

open access: yesBritish Journal of Pharmacology, Volume 182, Issue S1, Page S307-S403, December 2025.
The Concise Guide to Pharmacology 2025/26 marks the seventh edition in this series of biennial publications in the British Journal of Pharmacology. Presented in landscape format, the guide provides a comparative overview of the pharmacology of drug target families. The concise nature of the Concise Guide refers to the style of presentation, being clear,
Stephen P. H. Alexander   +31 more
wiley   +1 more source

Home - About - Disclaimer - Privacy